Best Life Sciences Companies in Lausanne, Switzerland
The 84 best Life Sciences companies in Lausanne, Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MindMaze Therapeutics.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Lausanne
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MindMaze Therapeutics Developer of neurotherapeutic solutions combining behavior, software, devices, and data | $361M | 0 mo ago | Public | — | 2012 | WordPressMySQLPHP+29 | — | — |
| 2 | MindMaze 🦄 Digital neurotherapeutic platform for digital assessments and therapeutics | $224M | 52 mo ago | Series B | 75 | 2012 | WordPressMySQLPHP+29 | 36 patents AI-driven neurorehabilitation devices for hand therapy, facial expression analysis, and SLAM tracking | 3 partnerships · 2 expansions |
| 3 | Asceneuron Developer of small molecules for the treatment of neurodegenerative diseases | $137M | 23 mo ago | Series C | 3 | 2012 | — | 159 patents Sulfoximine and piperazine-based glycosidase inhibitor compounds for therapeutic use | — |
| 4 | AC Immune Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative… | $120M | 29 mo ago | Public | 156 | 2003 | DrupalPHPBootstrap+24 | 1,305 patents Patents concentrated in chemistry & materials | — |
| 5 | Aleva Neuro Develops implantable deep brain stimulation systems that enables therapies for neurological diseases | $57M | 53 mo ago | Series E | 30 | 2008 | — | — | — |
| 6 | Sensimed Provider of a contact lens-based glaucoma monitoring platform | $42M | 155 mo ago | Acquired | — | 2003 | WordPressMySQLPHP+16 | 103 patents Measuring and monitoring intraocular pressure and ocular biomechanical properties for eye health. | — |
| 7 | Vandria Developer of in-vitro screening platform for drug discovery and development | $31M | 21 mo ago | Series A | 6 | 2018 | — | 38 patents Neuroprotective small‑molecule therapeutics using urolithin derivatives for ALS treatment | — |
| 8 | SamanTree Medical Developer of digital microscopy system for high-resolution imaging of tissue | $28M | 4 mo ago | Series C | 25 | 2014 | Cart FunctionalitySquarespace CommerceSquarespace+23 | 61 patents Fluorescence microscopy staining agents and motion‑artifact‑reduced imaging systems | 2 partnerships |
| 9 | HAYA Therapeutics Developer of RNA-based therapies for treating heart diseases | $25M | 13 mo ago | Series A | 38 | 2017 | WordPressMySQLPHP+18 | 18 patents RNA therapeutics targeting lncRNAs, super-enhancers, and transposable elements for disease modulation | — |
| 10 | Volumina Medical Developer of scaffold for the natural repair of 3D soft tissues | $21M | 26 mo ago | Series A | 9 | 2017 | WordPressMySQLPHP+11 | 11 patents Patents concentrated in health & consumer products | — |
| 11 | AB2 Bio Research-based company developing drugs for the treatment of inflammatory diseases | $21M | 125 mo ago | Series B | 10 | 2010 | Apache HTTP ServerGoogle Font APIModernizr+5 | 71 patents Patents concentrated in chemistry & materials | — |
| 12 | Lymphatica Medtech Developer of medical devices for the treatment of lymphatic diseases | $20M | 20 mo ago | Series B | 8 | 2015 | — | 4 patents Patents concentrated in health & consumer products | — |
| 13 | Endoart Developer of remote controlled implant for treatment of obesity | $13M | 242 mo ago | Acquired | — | 1998 | — | 39 patents Patents concentrated in health & consumer products | — |
| 14 | GenomSys Provider of solutions and systems for efficient genomic information processing | $9M | 81 mo ago | Series A | 20 | 2015 | WordPress Block EditorwpBakeryWordPress+22 | 199 patents Efficient compression, storage, indexing, and retrieval of large genomic sequence data. | 1 partnership |
| 15 | Artiria Developer of micro-navigation system for stroke surgery | $9M | 27 mo ago | Series A | 12 | 2019 | Webflowcore-jsjQuery+12 | — | 1 award |
| 16 | PB&B Cosmetic fillers and anti-aging medicine for healthcare aesthetics | $9M | 101 mo ago | Series A | 4 | 2013 | — | — | — |
| 17 | Amazentis Developing nutritional products to slow aging and improve quality of life | $9M | 86 mo ago | Series C | 45 | 2007 | — | 347 patents Urolithin-based nutraceutical formulations targeting autophagy, longevity, and athletic performance | — |
| 18 | Aspivix Provider of a next-generation suction-based cervical device for gynecological purposes | $7M | 43 mo ago | Series A | 9 | 2015 | WordPressMySQLPHP+29 | 32 patents Handheld gynecological examination devices for minimally invasive women's health diagnostics. | 1 launch |
| 19 | Glia Pharm Developer of treatments for neurological and psychiatric disorders | $6M | 30 mo ago | Series A | 9 | 2016 | — | — | — |
| 20 | Rheon Medical A non-invasively adjustable glaucoma drainage device for treating glaucoma | $6M | 66 mo ago | Series C | 7 | 2010 | WordPressMySQLPHP+20 | — | 1 expansion |
| 21 | Anecova Provider of assisted reproductive technologies | $5M | 102 mo ago | Deadpooled | 7 | 2004 | — | 47 patents Reusable intrauterine devices and protective sheaths for medical instruments | — |
| 22 | Atinary AI-based R&D operation automation platform for science labs | $5M | 32 mo ago | Seed | 10 | 2020 | — | — | 1 expansion · 1 award |
| 23 | Vanarix Developer of autologous hyaline cartilage microtissues for the treatment of cartilage defects | $4M | 23 mo ago | Series A | — | 2018 | — | 17 patents Patents concentrated in chemistry & materials | — |
| 24 | AlitheaGenomics Provider of transcriptomics solutions for research and biomarker discovery 37Talent top 38%Funding top 42%Tech top 42%News top 43% All 8 signals ▾Talenttop 38% Fundingtop 42% Techtop 42% Newstop 43% Growthtop 45% Moattop 48% Globalbottom 39% Marketbottom 26% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $4.2M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $4M | 3 mo ago | Seed | 9 | 2020 | WordPressApple iCloud MailMicrosoft 365+30 | — | 2 launchs · 1 partnership |
| 25 | Vaxeal Early-stage immunotherapy biotech focusing on Cancer, Hepatitis C and Malaria with therapies based on Long… | $4M | — | Deadpooled | — | 2009 | — | — | — |
| 26 | EarlySight Provider of retinal imaging solutions for retinal disorders | $3M | 9 mo ago | Seed | 11 | 2016 | WordPressMySQLPHP+20 | 6 patents Non‑invasive ocular diagnostics via transscleral optical imaging and retina image analysis | — |
| 27 | Infinite Vision Optics Adjustable intraocular lenses for cataract patients | $3M | 131 mo ago | Deadpooled | 7 | 2010 | — | — | — |
| 28 | Adaptyv Biosystems Provider of protein design, synthesis, testing, and validation services | $3M | 52 mo ago | Seed | 14 | 2021 | Webflow EcommerceWebflowKaTeX+16 | — | 1 job opening |
| 29 | Flowbone Developer of bone filling to treat osteoporosis | $2M | 44 mo ago | Seed | 6 | 2014 | WixSentryBootstrap+10 | — | — |
| 30 | Isospec Analytics Provider of drug and biomarker discovery for pharmaceutical companies | $2M | 26 mo ago | Seed | — | 2022 | — | — | 1 award |
| 31 | Nagi Bioscience Developer of a organism on a chip based technology | $2M | 78 mo ago | Seed | 10 | 2017 | — | 12 patents Microscopic imaging apparatus for nematodes and small biological specimens | — |
| 32 | autonomyo Provider of mobility device for disabled person 8Talent top 38%Funding bottom 42%Global bottom 36%Market bottom 14% All 4 signals ▾Talenttop 38% Fundingbottom 42% Globalbottom 36% Marketbottom 14% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $1.6M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 8/100 | $2M | 7 mo ago | Seed | 8 | 2020 | — | — | — |
| 33 | Saphetor Developer of platform for automated next-gen sequencing analysis | $1M | 124 mo ago | Seed | 70 | 2014 | WebflowMicrosoft AdvertisingjQuery+10 | — | — |
| 34 | Regenosca Developer of implant for bladder tissue reconstruction | $1M | 22 mo ago | Seed | 3 | 2017 | — | 6 patents Gradient-stiffness polymeric tissue scaffolds for regenerative medicine | — |
| 35 | Annaida Developer of sensor using magnetic resonance | $1M | 40 mo ago | Seed | 9 | 2018 | — | — | — |
| 36 | ORYL Photonics Developer of optical microscopes and light scattering devices for research | $953K | 11 mo ago | Series A | — | 2020 | — | — | — |
| 37 | ChemAlive Cloud-based computational platform for chemical research | $808K | 101 mo ago | Funding Raised | 2 | 2014 | — | — | — |
| 38 | SUN bioscience Provider of 3D cell culture systems for personalized medicine and organoid research | $664K | 55 mo ago | Funding Raised | — | 2015 | Cart FunctionalityWooCommerceWordPress+22 | — | — |
| 39 | Twiice Developer of exoskeleton for people suffering from mobility issues | $577K | 21 mo ago | Seed | 9 | 2016 | WordPressMySQLPHP+20 | — | — |
| 40 | Lyncee Tec Developer of digital holographic microscopy for life science and industrial applications | $342K | 64 mo ago | Acquired | 16 | 2003 | — | — | — |
| 41 | MoleSense Developer of molecular wearables intended for use in maternity care | $182K | 7 mo ago | Seed | — | 2025 | WebflowGSAPCloudflare Turnstile+10 | — | — |
| 42 | Emovo Care Developer of products intended to improve movement and rehabilitation outcomes | $154K | 32 mo ago | Seed | 5 | 2018 | — | — | — |
| 43 | Lucentix Developer of sensors for home-based blood testing | $131K | 132 mo ago | Deadpooled | — | 2014 | — | — | — |
| 44 | Rea Diagnostics Provider of a wearable diagnostic device to monitor the risk of preterm birth | $115K | 29 mo ago | Funding Raised | 6 | 2020 | — | — | — |
| 45 | Arkaïya Developer of probiotics to restore the gut microbiota | $108K | 54 mo ago | Funding Raised | 1 | 2015 | — | — | — |
Top 12 Life Sciences companies in Lausanne
#1
Public · Lausanne, Vaud · founded 2012$360.6Mraised▾
Developer of neurotherapeutic solutions combining behavior, software, devices, and data. The company offers a platform for brain health and recovery. It provides precision neurotherapeutics through a portfolio of solutions. The company also develops formulations for rare diseases. Its offerings include an immersive experience platform for brain recovery and a neurorehabilitation system. It provides a hand training peripheral and technology for digital motion assessments.
- Feb 2022Series B$105M
- Feb 2022Grant (prize money)$12.1M
- Oct 2021Conventional Debt$125M
- Sep 2017Angel—
#2
Series C · Lausanne, Vaud · founded 2014 · 25 employees$27.8Mraised▾
Developer of digital microscopy system for high-resolution imaging of tissue. The system allows rapid imaging of fresh tissue surfaces without slicing. It uses confocal microscopy for tissue visualization while preserving the specimen. The system includes a fluorescent stain and single-use device for imaging. Digital tools allow physicians to review images remotely and annotate areas of interest.
- Jan 2026Series C$23.7M
- Apr 2025Series B$6M
- Jul 2024Series B$14M
- Aug 2021Grant (prize money)$59K
#3
Seed · Lausanne, Vaud · founded 2020 · 9 employees$4.2Mraised▾
Provider of transcriptomics solutions for research and biomarker discovery. The company offers proprietary technology for RNA-seq of multiplex RNA samples for sequencing. The company also offers mRNA sequencing services and a kit that can be used for multiple samples.
- Mar 2026Seed$3.9M
- Mar 2024Seed$3.2M
- Mar 2023Conventional Debt$539.1K
- May 2022Seed$1M
#4
Series A · Lausanne, Vaud · founded 2017 · 38 employees$25Mraised▾
Developer of RNA-based therapies for treating heart diseases. It offers a platform that integrates multimodal functional genomics with computational tools to determine RNA-targeting modalities, such as modified antisense oligonucleotides (ASOs) to inhibit lncRNAs to prevent Fibrosis.
- May 2025Series A$65M
- Feb 2022Seed$5M
- May 2021Seed$20M
- Nov 2017Grant (prize money)$40.3K
#5
Series C · Lausanne, Vaud · founded 2012 · 3 employees$137Mraised▾
Developer of small molecules for the treatment of neurodegenerative diseases. The company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease.
- Jul 2024Series C$100M
- May 2022Grant (prize money)—
- Oct 2016Grant (prize money)—
- Sep 2015Series A$30.6M
#6
Seed · Lausanne, Vaud · founded 2016 · 11 employees$2.7Mraised▾
Provider of retinal imaging solutions for retinal disorders. By using the technology doctors can understand and visualize the origins of many diseases such as age-related macular degeneration. It allows the ophthalmologist to measure the cell density or size of the retina. It helps ophthalmologists to see the micro-vasculature structure and the small capillaries in retinal disorder.
- Sep 2025Seed$3.9M
- Oct 2023Seed$111.3K
- May 2021Seed$2.6M
- Feb 2020Conventional Debt$102.9K
#7
Series B · Lausanne, Vaud · founded 2015 · 8 employees$19.6Mraised▾
Developer of medical devices for the treatment of lymphatic diseases. The company offers "Lymph Drain" a catheter system implanted subcutaneously that intended to recirculate lymph inside the patient body, re-establishing the physiological fluid equilibrium.
- Oct 2024Series B$19.6M
- Jul 2022Grant (prize money)$51.1K
- Dec 2020Series A—
- Sep 2019Grant (prize money)$2M
#8
Seed · Lausanne, Vaud · founded 2020 · 8 employees$1.6Mraised▾
Autonomyo provides mobility devices for disabled persons. It helps people with neurological gait disorders to walk again. The lower limb exoskeleton enables people with muscular and neurological deficiencies to walk.
- Nov 2025Seed$1.6M
- Dec 2021Conventional Debt—
#9
Series A · Lausanne, Vaud · founded 2018 · 6 employees$30.7Mraised▾
Developer of in-vitro screening platform for drug discovery and development. The company has created a platform for identifying and discovering small compounds (mitophagy inducers). It aids in the identification of the leading candidate molecule linked to age-related and chronic diseases.
- Aug 2024Series A—
- Dec 2023Series A$20.6M
#10
Public · Lausanne, Vaud · founded 2003 · 156 employees$119.8Mraised▾
Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases. It has a diversified pipeline of drugs for Alzheimer’s disease, Parkinson’s, Down syndrome, and Glaucoma. The company has technology platforms, SupraAntigen and Morphomer which generate sensitive diagnostics, highly specific biologics and small molecule drugs.
- Dec 2023Post IPO—
- Sep 2022Grant (prize money)$500K
- Sep 2019Grant (prize money)—
- Dec 2018Post IPO$50M
#11
Series A · Lausanne, Vaud · founded 2020$953.1Kraised▾
Developer of optical microscopes and light scattering devices for research. The company provides an ORYL screener, wide-field nonlinear microscope, and high-efficiency second-harmonic scattering system. These systems are uses for crystallization, aggregation, surface electrostatics, and surface chemistry in solution.
- Jul 2025Series A—
- Jan 2024Seed$953.1K
#12
MindMaze 🦄Series B · Lausanne, Vaud · founded 2012 · 75 employees$223.5Mraised▾
Developer of digital neurotherapeutics (DTx) devices designed to accelerate the brain's ability to recover, learn and adapt. The company utilizes immersive virtual reality, motion capture and neurophysiological recording technologies to build novel interfaces for neurorehabilitation, game training and three-dimensional imaging in real-time, enabling patients to restore motor function after stroke or brain trauma.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Lausanne is moving
A read on the academic research around Biotechnology in Lausanne — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 50 papers.
- University of Lausanne34
- École Polytechnique Fédérale de Lausanne18
- University Hospital of Lausanne5
- Centre universitaire de médecine générale et santé publique, Lausanne1
- Gene2
- Argonaute2
- Jurkat cells2
- microRNA2
- Immunoprecipitation2
- Cell culture3
- In vitro2
- Messenger RNA2
- Transfection2
- Translation (biology)2
- Antifungal2
- Biotin2
- Spheroid2
- Function (biology)2
- HEK 293 cells2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.